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ABSTRACT
Objective: The objective of this study was to evaluate and compare the hepatoprotective effect of clearliv tablets with silymarin in patients with 
alcoholic liver disease.
Methods: This was a prospective, randomized, multicenter, open-label, parallel group interventional clinical endpoint study (Phase IIa). Patients 
attending general medicine outpatient department were screened for alcoholic liver disease using the serum biochemical liver function test and 
ultrasonogram abdomen and tested whether they satisfy the selection criteria, and 24 patients were then enrolled in the study. The study drug, 
namely clearliv tablets of Apex Laboratories Pvt. Ltd., was administered to Group A and tablet silymarin was administered to Group B from day 1 to 
day 56. Patients were reviewed once in 2 weeks. Liver function test was repeated, and patients were enquired of their well-being and any adverse 
events.
Results: The demographic characters and body weight of the subjects showed no significant difference between the groups. There is a significant 
improvement (p<0.05) in the aspartate transaminase (AST), alanine transaminase (ALT), and total bilirubin (TB) levels on 28th and 56th days in 
both silymarin and clearliv groups. Of the 2 groups, there is higher significance of improvement in clearliv group (p<0.001), compared to silymarin 
group. Clearliv group started showing a significant reduction in AST and ALT levels in the first 14 days of the study period. On comparing the mean 
percentage reduction in the levels of AST (35.7% and 35%), ALT (26.7% and 24.3%), and TB (26.7% and 25%), it was found that clearliv is showing 
a better percentage of reduction of the above parameters compared to silymarin. There were reports of adverse effects such as loss of appetite and 
gastritis in both the groups.
Conclusion: This clinical study proves that clearliv is functioning as a hepatoprotective drug. It is offering a better hepatoprotection compared to 
silymarin. Clearliv tablets can be indicated for the management of liver dysfunction, which occurs due to alcoholic liver damage. It may also be used in 
similar manner in cases of viral hepatitis, drug-induced liver damage, acute and chronic hepatitis.
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INTRODUCTION
In the year 2010, the global burden of alcoholic liver diseases was 
large and resulted in 493, 000 deaths and 14,544,000 disability-
adjusted life years. This burden represented 0.9% of all deaths and 
0.6% of all disability-adjusted life years in 2010 [1]. Alcoholic liver 
disease encompasses a clinical-histologic spectrum including fatty 
liver, alcoholic hepatitis, and cirrhosis with its complications [2]. The 
World Health Organization (WHO) estimates that alcohol is now the 
third highest risk factor for premature mortality, disability, and loss of 
health worldwide [3]. There is a growing incidence of hepatocellular 
carcinoma (HCC) worldwide. The annual global incidence of HCC is 
over 500,000 cases. The highest incidence of HCC is observed in Asia 
and Africa, associated with the high prevalence of hepatitis in these 
regions [4]. The hallmark of therapy in alcoholic liver diseases has been 
abstinence from alcohol and nutritional therapy. Role of steroids has 
been accepted in the treatment; however, the effectiveness of therapy 
should be assessed after 1 week of treatment. Pentoxifylline has been 
equally effective, especially in patients with renal dysfunction or 
hepatorenal syndrome. The use of biologics has been disappointing in 
the treatment of alcoholic liver diseases [5].
India is the largest producer of medicinal plants. The medicinal plants 
have very important role in the health of human beings as well as 
animals. As per the WHO estimates, about three-quarters of the world’s 
population currently use herbs and other traditional medicines to cure 
various diseases, including liver disorders [6].
Clearlivis, a research product (ferbal medicine), was developed 
by Apex Laboratories Ltd., for hepatoprotection. Clearliv has a 
composition as follows: Ricinus communis: 42.85 mg, Phyllanthus 
niruri: 25 mg, Eclipta alba: 15 mg, Boerhaavia diffusa: 12.5 mg, 
Tinospora cordifolia: 10 mg, Tribulus terrestris: 14.28 mg, Tephrosia 
purpurea: 11.11 mg, Indigofera tinctoria: 9.37 mg, Andrographis 
paniculata: 6.25 mg, Rubia cordifolia: 5 mg, Terminalia chebula: 
12.5 mg, Curcuma longa: 3.5 mg, and Aconitum Heterophyllum: 10 mg. 
The formulation has been validated scientifically and traditional 
claims have been supported by scientific data. Standardization of all 
the extracts has been established without losing the essence of the 
Ayurvedic tradition. In an animal study conducted by Kumar et al., 
it was shown that clearliv in doses of 800 and 1000 mg/Kg has a 
significant hepatoprotective action against various hepatotoxicant-
induced liver necrosis and injury [7]. Clearliv tablets are formulated 
in such a way that it offers three clear benefits in liver care, i.e., clearliv 
tablets conserves the liver, controls the liver damage and corrects 
the liver functions. Clearliv tablet is indicated for the management 
of liver dysfunction which may occur due to alcoholic liver damage, 
viral hepatitis, drug-induced liver damage, and acute and chronic 
hepatitis. Clearliv tablet can also be prescribed during pregnancy for 
intrahepatic cholestasis and associated constipation.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Herbal medicines have been used in the treatment of liver diseases 
for a long time; however, standardization of herbal medicines has 
been a problem. Hence, the rationale behind this study is that we have 
standardized a herbal medicine for liver disease, and if it is efficacious 
without any side effects, then it can be useful for the population 
suffering from liver disease at a cheaper cost compared to the current 
treatments available. Prospective, randomized, controlled clinical 
trials are also lacking to support their efficacy [8]. Hence, with an aim 
to evaluate the efficacy and safety of the clearliv tablets in patients 
with liver dysfunction, like alcoholic liver disease in comparison with 
standard drug such as silymarin, the present study was conducted.
METHODS
This was a prospective, randomized, multicenter, open-label, parallel 
group interventional clinical endpoint study (Phase IIa). The study 
was conducted at two centers in India at Mahatma Gandhi College 
and Hospital, Pondicherry, and PM Medical Centre, Walajapet, Tamil 
Nadu, according to good clinical practice. The study was initiated after 
obtaining proper ethical committee approvals in ki3 ethics committee. 
The study was registered in the Clinical Trial Registry of India (No: 
CTRI/2018/03/012644), and Drug Control General of India (AYUSH) 
was notified (Notification No: 2730). Informed written consent was 
obtained from the patients attending general medicine outpatient 
department. Then, they underwent general and systemic examination 
followed by laboratory tests for hematology, blood biochemistry, blood 
microbiology, urine analysis, electrocardiogram, and chest X-ray for 
initial evaluation and were screened for alcoholic liver disease using 
the serum biochemical liver function test and ultrasound sonography 
abdomen and tested whether they satisfy the selection criteria, and 
24 patients were then enrolled in the study.
Patients recruited in the study were belonged to:
a. Either sex and 18–70 years of age, with chronic alcohol intake.
b. Patients in whom serum aspartate transaminase (AST) and alanine 
transaminase (ALT) were typically elevated to a level of 2–6 times 
the upper limit of normal, and patients who tested negative for HIV, 
hepatitis B, and C.
c. Female patients who tested negative for pregnancy (up to 2 weeks 
before the study) were included in the study.
Patients who were excluded from the study were as follows:
a. Those who had liver disease with the cause different from that of 
alcohol-induced liver disease.
b. Patients who were suffering from hepatic failure, hepatic cirrhosis, 
Wilson’s disease, malignant tumor, serious metabolic disease, severe 
renal disease, severe pulmonary disease, severe cardiovascular disease, 
severe nervous disease/psychiatric disorder, and muscular disorders.
c. Pregnant or lactating women.
d. Patients with comorbidities and reduced life expectancy, patients 
known to be dependent on drugs, and patients with any known 
hypersensitivity or allergy to any component of the drugs involved 
in the study.
e. Patients who were on medications that may affect treatment such 
as colchicine, penicillamine, corticosteroids, ursodeoxycholic acid, 
pentoxifylline, long-term use of statins, neuroleptics, anti-convulsant 
medications, and high-dose acetaminophen (>2.5 g/day).
f. Patients who may have participated in recent past (past 3 months) 
in a clinical trial.
Eligible subjects were randomly selected through computer-generated 
randomization using simple randomization and were divided into 
Groups A and B. The study drug, clearliv tablet (2 tablets twice daily 
postprandial), was administered to Group A and silymarin tablet 
(70 mg twice daily post prandial) was administered to Group B from 
day 1 to day 56 at the specified time of the day. The drugs were provided 
to the patients at each visit (once in 2 weeks) along with a patient 
diary to monitor the compliance. The patients were reviewed on days 
14, 28, 42, and 56. Liver function test was repeated, and the patients 
were enquired for their well-being, adverse events, and compliance. 
Patients were strictly advised not to consume alcohol throughout the 
study period. Counseling for alcohol abstinence was given at each visit. 
Further course of the treatment for the test subjects was based on the 
discretion of the investigator. The reports were compiled. Continuous 
data were reported using the descriptive statistics using mean and 
standard deviation. For analyzing continuous data, student’s t-test 
followed by Mann–Whitney U-test and two-way ANOVA was applied. 
(p<0.05) was considered as statistically significant. All the statistical 
analyses were performed using SPSS 23.0 software.
RESULTS
All the 24 patients selected for the study completed the study. There 
were no dropouts. Complete disposition of the study participants is 
given in Table 1.
The efficacy of both control and test drugs was found to be similar, 
and there was no statistically significant difference observed between 
the two. The efficacy was observed as an improvement in the AST, 
ALT, and total bilirubin (TB) levels from the baseline as a result of the 
treatment with the two drugs. Table 2 enumerates the comparison of 
mean percentage improvement between the control and the test groups 
(Figs. 1 and 2).
Gastritis and loss of appetite were the two adverse events observed 
during the study period. None of the patients experienced nausea, 
vomiting, diarrhea, cardiovascular side effects, or neurological side 
effects. Among 12 subjects in the treatment group, four subjects reported 
loss of appetite and five subjects reported symptoms of gastritis which 
resolved on its own. Among the 12 subjects in the control group, 
6 reported a decrease in appetite and 8 subjects reported symptoms 
of gastritis which resolved on its own. No other serious adverse events 
were reported during the study period. Table 3 enumerates the adverse 
events recorded during the study period.
Table 1: Baseline demographic parameters




Gender, n (%) male 100 100
Age 39.08±7.76 36.3±4.3
Body weight 76.8±7.87 78.03±7.04
AST level (IU) 141±19.04 142.58±22.73
ALT level (IU) 68.2±11.09 69±12.22
TB (mg/dl) 1.8±0.48 1.87±0.30
AST: Aspartate transaminase, ALT: Alanine transaminase, TB: Total bilirubin, 
#: Two-way ANOVA followed by Bonferroni post-test, p value was not significant 
for baseline parameters
Fig. 1: Comparison of mean percentage reduction in aspartate 
transaminase levels (n=12 subjects per group)
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DISCUSSION
There was no significant difference between the demographic 
characteristics of the two groups. None of the patients showed any 
discomfort in the usage of clearliv. As is observed from the measurement 
of primary outcome, there is an extremely significant improvement in 
the AST, ALT, and TB levels on 28th day and 56th day of the treatment, 
both in the silymarin and clearliv groups. However, it is noticeable that 
the patients in the clearliv group started showing a significant reduction 
in AST and ALT levels in the first 14 days of the study period which was 
not seen the silymarin (control) group. A comparison of the percentage 
reduction in the levels of AST, ALT, and TB (Table 2) showed that both 
silymarin and clearliv were equally effective, but clearliv demonstrated 
a better overall reduction in percentage values of these parameters. 
There was a remarkable overall improvement in the well-being of the 
study subjects, both in the test and the control groups. However, the 
improvement was better in clearliv group.
Thus, clearliv is showing a hepatoprotective action. The main 
components of clearliv which includes Ricinus communis or castor 
plant has shown hepatoprotective activity in a previous studies done 
by Pingale et al., [9] and Visen et al., [10], where the extracts of Ricinus 
communis leaves was used against hepatosuppression induced by 
carbon tetrachloride and galactosamine-induced hepatic damage, 
respectively. The hepatoprotective activity may be due to the important 
phytochemical constituents such as flavonoids, saponins, glycosides, 
alkaloids, and steroids in this herb. It was also found out that there were 
two active intermediate products from the herb, namely ricinine and 
N-demethyl-ricinine, which were showing hepatoprotective activity.
The other major component, namely Phyllanthus niruri, which 
originated in India, usually occurring as a winter weed throughout 
the hotter parts, has been shown to have hepatoprotective properties 
because of the presence of active phytochemicals, flavonoids, alkaloids, 
terpenoids, lignans, polyphenols, tannins, coumarins, and saponins. 
Extracts of this herb have been proven to have therapeutic effects in 
many clinical studies [11,12]. The hepatoprotective effects of other 
components, namely Eclipta alba, Andrographis paniculata, Tinospora 
cordifolia, and Tephrosia purpurea, have been proved in previous 
studies, by doing biochemical and histopathological assay of liver 
specimens [13-15].
All the herbs included in clearliv have antioxidant property. The 
hepatoprotective activity of clearliv is evident from the normalization 
of AST, ALT, and TB levels. Hence, it can be postulated that the 
hepatoprotective effect of clearliv tablets is due to the inhibitory effect 
of the active phytochemicals of each herb, on the free radical formation.
CONCLUSION
The results of the clinical study have shown that clearliv is an effective 
hepatoprotective drug offering a comparatively better hepatoprotection 
as compared to silymarin. A significant reduction in the AST, ALT, and 
TB levels was observed from 14th day onward in the clearliv-treated 
group. Both the clearliv and silymarin treatment groups showed a 
better reduction in the above parameters from baseline at 28th and 
56th days of the treatment.
Hence, it can be concluded that clearliv tablets can be indicated for the 
management of liver dysfunction, which occurs due to alcoholic liver 
damage. It may also be used effectively in case of viral hepatitis, drug-
induced liver damage, and acute and chronic hepatitis. We can clearly 
say that clearliv is not only an effective but also a safe drug to be used 
in patients with alcoholic liver disease, which may be evaluated further 
by doing large-scale clinical studies on liver dysfunction caused due to 
factors other than alcoholic liver disease.
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Fig. 2: Comparison of mean percentage reduction in alanine 
transaminase levels (n=12 subjects per group)
Table 2: Comparison of percentage reduction in AST, ALT, and TB 
levels at various follow-up visits








Day 14 28 34 >0.05 NS
Day 28 39 38 >0.05 NS
Day 56 38 35 >0.05 NS
ALT
Day 14 28 30 >0.05 NS
Day 28 18 20 >0.05 NS
Day 56 27 30 >0.05 NS
TB
Day 14 45 45 >0.05 NS
Day 28 10 9 >0.05 NS
Day 56 20 26 >0.05 NS
AST: Aspartate transaminase, ALT: Alanine transaminase, TB: Total bilirubin, 
#: Two-tailed student t-test followed by Mann–Whitney U-test was performed. 
p<0.05 is considered statistically significant, NS: Not significant
Table 3: Adverse events occurred during the study period







test group  
Clearliv 
(n=12)
1 Gastritis 8 4
2 Nausea 0 0
3 Vomiting 0 0
4 Diarrhea 0 0
5 Loss of appetite 6 5
6 Cardiovascular side effects 0 0
7 Neurological side effects 0 0
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